Literature DB >> 2878859

Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.

H Sandberg-Gertzén, G Järnerot, K Bukhave, K Lauritsen, J Rask-Madsen.   

Abstract

Azodisal sodium is a highly effective means of oral delivery of 5-amino-salicylic acid to the colonic mucosa. Administration of this drug to patients intolerant of sulphasalazine, however, occasionally results in liquid stools. In preliminary experiments, which comprised 10 healthy volunteers treated with colectomy for ulcerative colitis, ileostomy fluid output increased (p less than 0.001) during oral intake of azodisal sodium (1 g/day). In a double blind, placebo controlled crossover study, comprising eight similar volunteers, ileostomy fluid output increased (p less than 0.05) in a dose related manner during intake of azodisal sodium (1 g/day vs 2 g/day) compared with placebo or sulphasalazine (2 g/day). Concentrations of prostaglandin (PG)F2 alpha in free ileal water determined by equilibrium in vivo dialysis of ileostomy contents decreased (p less than 0.05) during intake of azodisal sodium (2 g/day), whereas concentrations of PGE2 and the output of PGE2, PGF2 alpha, and 'PGE2 + PGF2 alpha' remained unchanged. Thus increased formation of PGs is apparently not the cause of increased ileostomy fluid output associated with azodisalicylate intake.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878859      PMCID: PMC1434079          DOI: 10.1136/gut.27.11.1306

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  Bloody diarrhea--a new complication of sulfasalazine.

Authors:  S L Werlin; R J Grand
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

2.  Will there be a next generation of sulfasalazine?

Authors:  P Goldman
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

3.  Sulfasalazine-induced exacerbation of ulcerative colitis.

Authors:  A G Schwartz; S R Targan; A Saxon; W M Weinstein
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

4.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

5.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

6.  Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).

Authors:  P A van Hees; J H Tuinte; J M van Rossum; J H van Tongeren
Journal:  Gut       Date:  1979-04       Impact factor: 23.059

7.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

8.  Prostaglandin E2 in jejunal fluids and its potential diagnostic value for selecting patients with indomethacin-sensitive diarrhoea.

Authors:  K Bukhave; J Rask-Madsen
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

9.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

10.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

View more
  15 in total

1.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

Authors:  A Ireland; C H Mason; D P Jewell
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

Review 2.  Medical treatment of inflammatory bowel disease: new therapies, new drugs.

Authors:  L R Sutherland
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

3.  Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro.

Authors:  K J Goerg; R Wanitschke; P H Diehl; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

Review 4.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

5.  Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.

Authors:  A H Raimundo; D H Patil; P G Frost; D B Silk
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

6.  Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.

Authors:  K Lauritsen; L Staerk Laursen; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

7.  Olsalazine in maintenance of clinical remission in patients with ulcerative colitis.

Authors:  J P Wright; E A O'Keefe; L Cuming; K Jaskiewicz
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

8.  Influence of olsalazine on gastrointestinal transit in ulcerative colitis.

Authors:  S S Rao; N W Read; C D Holdsworth
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

9.  Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

Authors:  S Kiilerich; K Ladefoged; T Rannem; P J Ranløv
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

10.  Effect of olsalazine on sodium-dependent bile acid transport in rat ileum.

Authors:  A Chawla; P I Karl; R N Reich; G Narasimhan; G A Michaud; S E Fisher; B L Schneider
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.